Skip to the beginning of the images gallery

Bevacizumab - ~25mg/ml(in buffer,PH6.2),≥95%, high purity , CAS No.216974-75-3

1 Citations

Moligand™

≥95%
~25mg/ml(in buffer,PH6.2)

Features and benefits

Item Number

B303060

Grouped product items
SKU	Size	Availability	Price	Qty
B303060-1mg	1mg	Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!	$157.90
B303060-5mg	5mg	Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!	$652.90

View related series

Click to view target information: VEGFA

Protein Tyrosine Kinase/RTK VEGFR

Basic Description

Product Name	Bevacizumab - ~25mg/ml(in buffer,PH6.2),≥95%, high purity , CAS No.216974-75-3
Specifications & Purity	Moligand™, ≥95%, ~25mg/ml(in buffer,PH6.2)
Grade	Moligand™
Product Description	Bevacizumab is a humanized monoclonal antibody that binds to all VEGF-A with high affinity and specificity.

Concentration

~25mg/ml(in buffer,PH6.2)

Storage Temp

Protected from light,Store at -20°C

Shipped In

Ice chest + Ice pads

CAS

216974-75-3

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Find and download the COA for your product by matching the lot number on the packaging.

6 results found

Lot Number	Certificate Type	Date	Item
A2214365	Certificate of Analysis	Nov 05, 2024	B303060
A2214366	Certificate of Analysis	Nov 05, 2024	B303060
L2201633	Certificate of Analysis	Aug 26, 2022	B303060
L2201667	Certificate of Analysis	Aug 26, 2022	B303060
G2207118	Certificate of Analysis	Jun 14, 2022	B303060
G2207121	Certificate of Analysis	Jun 14, 2022	B303060

Citations of This Product

How to Cite Aladdin Scientific Products?

1. Wenjuan Huang, Liwen Wang, Ruhui Yang, Ronggui Hu, Qinxiang Zheng, Xingjie Zan. (2022) Combined delivery of small molecule and protein drugs as synergistic therapeutics for treating corneal neovascularization by a one-pot coassembly strategy. Materials Today Bio, 17 (100456). [PMID:36281304] [10.1016/j.mtbio.2022.100456]

References

1. Wenjuan Huang, Liwen Wang, Ruhui Yang, Ronggui Hu, Qinxiang Zheng, Xingjie Zan. (2022) Combined delivery of small molecule and protein drugs as synergistic therapeutics for treating corneal neovascularization by a one-pot coassembly strategy. Materials Today Bio, 17 (100456). [PMID:36281304] [10.1016/j.mtbio.2022.100456]

Solution Calculators

Molarity Calculator

Determine the necessary mass, volume, or concentration for preparing a solution.

Dilution Calculator

Determine the dilution needed to prepare a stock solution.

Bevacizumab - ~25mg/ml(in buffer,PH6.2),≥95%, high purity , CAS No.216974-75-3

Basic Description

Product Properties

Associated Targets(Human)